Now showing items 1-7 of 7
Time for gender mainstreaming in editorial policies.
(International AIDS Society., 2011)
The HIV epidemic has been continuously growing among women, and in some parts of the world, HIV-infected women outnumber men. Women’s greater vulnerability to HIV, both biologically and socially, influences their health ...
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
No abstract available.
Empowering women in human immunodeficiency virus prevention.
Women comprise one-half of people infected with the human immunodeficiency virus in the world, and about 70% of them live in sub-Saharan Africa. Advancing, untreated HIV disease in women has resulted in substantial declines ...
Genital tract inflammation during early HIV-infection predicts higher plasma viral load set point in women.
(Oxford University Press., 2011)
Background. The biggest challenge in human immunodeficiency virus type 1 (HIV-1) prevention in Africa is the high HIV-1 burden in young women. In macaques, proinflammatory cytokine production in the genital tract is necessary ...
Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial.
(Lippincott Williams & Wilkins., 2012)
Objective: To assess the role of natural killer (NK) cells in HIV acquisition. Design: We conducted a nested case–control substudy to the Center for the AIDS Programme of Research in South Africa (CAPRISA004) tenofovir gel ...
Gender-sensitive reporting in medical research.
(BioMed Central., 2012)
Sex and gender differences influence the health and wellbeing of men and women. Although studies have drawn attention to observed differences between women and men across diseases, remarkably little research has ...
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
(American Association for the Advancement of Science., 2010)
The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the ...